C12N 2501/25
Tumour necrosing factors [tnf]
Official title: Tumour necrosing factors [TNF]
C12N2501/25 (Tumour necrosing factors [tnf]) appears on 259 US grants and 576 published applications in this corpus.
Search patents in C12N- Granted patents
- 259
- Published applications
- 576
- Assignees
- 337
- Inventors
- 1,176
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 7 | 0 |
| 2000 | 4 | 0 |
| 2001 | 8 | 4 |
| 2002 | 5 | 11 |
| 2003 | 6 | 6 |
| 2004 | 3 | 10 |
| 2005 | 2 | 11 |
| 2006 | 3 | 11 |
| 2007 | 0 | 5 |
| 2008 | 1 | 10 |
| 2009 | 2 | 15 |
| 2010 | 6 | 12 |
| 2011 | 4 | 11 |
| 2012 | 3 | 9 |
| 2013 | 12 | 14 |
| 2014 | 12 | 15 |
| 2015 | 5 | 24 |
| 2016 | 9 | 24 |
| 2017 | 14 | 18 |
| 2018 | 14 | 22 |
| 2019 | 14 | 35 |
| 2020 | 10 | 40 |
| 2021 | 21 | 50 |
| 2022 | 13 | 46 |
| 2023 | 18 | 29 |
| 2024 | 29 | 60 |
| 2025 | 21 | 55 |
| 2026 | 8 | 29 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- B-cell cultivation method4 Aug 2026US 12,698,474 B2Hoffmann-La Roche Inc.
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion7 Jul 2026US 12,673,982 B2Iovance Biotherapeutics, Inc.
- Biocompatible conditioned cell medium compositions and uses thereof16 Jun 2026US 12,655,384 B2Cellum Biomedical, Inc.
- Genomic engineering of pluripotent cells2 Jun 2026US 12,642,852 B1Fate Therapeutics, Inc.
- Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy28 Apr 2026US 12,612,598 B2Iovance Biotherapeutics, Inc.
- Single b-cell cultivation method24 Sep 2026US 2026/0285949 A1Hoffmann-La Roche Inc.
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion17 Sep 2026US 2026/0274920 A1Iovance Biotherapeutics, Inc.
- Thymic cell compositions and methods of making3 Sep 2026US 2026/0256842 A1Thymmune Therapeutics, Inc.
- Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy3 Sep 2026US 2026/0258358 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013
- Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens124US 5,994,126 AThe Rockefeller University · 1999
- Modulation of stem and progenitor cell differentiation, assays, and uses thereof94US 7,498,171 B2Anthrogenesis Corporation · 2009
- Culturing monocytes with IL-4, TNF-.alpha. and GM-CSF TO induce differentiation to dendric cells86US 5,849,589 ADuke University · 1998
- Methods and compositions for obtaining mature dendritic cells70US 6,274,378 B1The Rockefeller University · 2001